DCT

1:24-cv-11529

Endo USA Inc v. Gland Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:24-cv-11529, D.N.J., 12/31/2024
  • Venue Allegations: Venue is asserted on the basis that the defendant is a foreign corporation not resident in any U.S. judicial district, and alternatively, that the defendant plans to sell its accused products in New Jersey.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's VASOSTRICT® product constitutes an act of infringement of eight U.S. patents.
  • Technical Context: The technology relates to stable, injectable pharmaceutical formulations of vasopressin, a peptide hormone used to increase blood pressure in patients with life-threatening hypotension.
  • Key Procedural History: The asserted patents are listed in the FDA's "Orange Book" for VASOSTRICT®. The suit was triggered by a Paragraph IV Certification notice letter, sent by Gland Pharma no earlier than November 18, 2024, in which Gland alleged that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by its proposed generic product.

Case Timeline

Date Event
2012-09-25 Original New Drug Application (NDA 204485) for VASOSTRICT® submitted
2014-04-17 FDA first approved NDA for VASOSTRICT®
2015-01-30 Earliest Priority Date for all Patents-in-Suit
2018-03-20 U.S. Patent No. 9,919,026 Issued
2018-03-27 U.S. Patent No. 9,925,233 Issued
2018-03-27 U.S. Patent No. 9,925,234 Issued
2018-05-08 U.S. Patent No. 9,962,422 Issued
2018-05-15 U.S. Patent No. 9,968,649 Issued
2018-05-22 U.S. Patent No. 9,974,827 Issued
2018-05-29 U.S. Patent No. 9,981,006 Issued
2018-07-03 U.S. Patent No. 10,010,575 Issued
2020-04-15 FDA approved supplemental NDA for VASOSTRICT® Premixed Products
2021-04-21 FDA approved supplemental NDA for VASOSTRICT® Premixed Products
2024-11-18 Gland sent Paragraph IV Notice Letter to Endo
2024-12-31 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,919,026 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: March 20, 2018

The Invention Explained

  • Problem Addressed: The patent addresses the problem that vasopressin, a peptide hormone, is prone to degradation, limiting the long-term stability of its liquid formulations needed for treating hypotension. ʼ026 Patent, col. 5:19-23
  • The Patented Solution: The invention provides a shelf-stable pharmaceutical composition of vasopressin for intravenous use. Stability is achieved by formulating vasopressin within a specific, narrow pH range (3.0 to 4.5) using a buffer (e.g., acetate), which is shown to minimize the formation of degradation-related impurities over time. ʼ026 Patent, abstract ʼ026 Patent, col. 2:24-41 '026 Patent, FIG. 9
  • Technical Importance: Creating a stable, ready-to-use injectable vasopressin formulation is clinically significant for treating acute hypotensive emergencies, as it eliminates the need for reconstitution and reduces concerns about diminished potency due to degradation.

Key Claims at a Glance

  • The complaint asserts infringement of "one or more claims" of the '026 patent Compl. ¶45 Independent claim 1 is representative:
  • A pharmaceutical composition for intravenous administration, comprising, in a unit dosage form:
    • from about 0.1 μg/mL to about 2 μg/mL of vasopressin;
    • impurities that are present in an amount of 0.1% to 1.7%, wherein the impurities are determined based on a reporting threshold of 0.05% relative to the vasopressin peak;
    • from about 1 mM to about 10 mM acetate buffer;
    • wherein the unit dosage form has a pH of 3.0 to 4.5;
    • and wherein the unit dosage form exhibits no more than about 10% degradation of vasopressin or the pharmaceutically acceptable salt thereof after storage at 25° C. for at least about one month.
  • The complaint reserves the right to assert other claims, including dependent claims.

U.S. Patent No. 9,925,233 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: March 27, 2018

The Invention Explained

  • Problem Addressed: This patent addresses the same problem as the '026 Patent: the instability of vasopressin in liquid formulations. ʼ233 Patent, col. 5:19-23
  • The Patented Solution: The '233 patent claims a method for increasing blood pressure in a human patient. The method involves administering a specific, highly stable vasopressin formulation that is defined by its composition (including vasopressin, acetate buffer, and dextrose) and its stability characteristics (exhibiting no more than about 4.0% degradation after storage at 25°C for one month). '233 Patent, claim 1
  • Technical Importance: This patent protects the specific use of a highly stable formulation for treating hypotension, linking the formulation's unique characteristics to a therapeutic outcome.

Key Claims at a Glance

  • The complaint asserts infringement of "one or more claims" of the '233 patent Compl. ¶55 Independent claim 1 is representative:
  • A method of increasing blood pressure in a human in need thereof, the method comprising:
    • providing a unit dosage form comprising about 0.1 μg/mL to about 1 μg/mL vasopressin, about 1 mM to about 10 mM acetate buffer, and about 5% dextrose, having a pH of 3.6 to 3.9, which exhibits no more than about 4.0% vasopressin degradation after storage at 25°C for about one month; and
    • intravenously administering the unit dosage form to the human.
  • The complaint reserves the right to assert other claims, including dependent claims.

U.S. Patent No. 9,925,234 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: March 27, 2018
  • Technology Synopsis: This patent claims a method of increasing blood pressure by administering a vasopressin formulation defined by specific components (vasopressin, chlorobutanol, acetic acid, water) and a stability profile (less than about 5% degradation after 24 hours at a concentration of 0.1 units/mL). '234 Patent, claim 1 It focuses on a different formulation composition and stability metric compared to the '026 and '233 patents.
  • Asserted Claims: One or more claims are asserted. Compl. ¶65
  • Accused Features: The accused features are the composition and method of use of Gland's proposed generic vasopressin product as described in its ANDA. Compl. ¶65

U.S. Patent No. 9,962,422 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: May 8, 2018
  • Technology Synopsis: This patent claims a method of increasing blood pressure by administering a vasopressin formulation defined by its components (vasopressin, acetate buffer, and dextrose), a specific pH range (3.7 to 3.75), and a stability profile (no more than 2% degradation after one month at 25°C). '422 Patent, claim 12 This patent appears to narrow the pH and degradation parameters relative to the '233 patent.
  • Asserted Claims: One or more claims are asserted. Compl. ¶75
  • Accused Features: The accused features are the composition and method of use of Gland's proposed generic vasopressin product. Compl. ¶75

U.S. Patent No. 9,968,649 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: May 15, 2018
  • Technology Synopsis: This patent claims a method of increasing blood pressure using a vasopressin formulation defined by the presence of specific, low-level impurities (SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 10, and SEQ ID NO. 11) and a specific pH range (3.6 to 3.9). '649 Patent, claim 1 This patent focuses on the impurity profile as a key characteristic.
  • Asserted Claims: One or more claims are asserted. Compl. ¶85
  • Accused Features: The accused features are the composition, impurity profile, and method of use of Gland's proposed generic vasopressin product. Compl. ¶85

U.S. Patent No. 9,974,827 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: May 22, 2018
  • Technology Synopsis: This patent claims a method of increasing blood pressure using a vasopressin formulation defined by its components (acetate buffer), pH (3.4 to 3.6), and storage stability (at 2-8°C for at least one week). '827 Patent, claim 1 The claims in this patent focus on refrigerated storage stability.
  • Asserted Claims: One or more claims are asserted. Compl. ¶95
  • Accused Features: The accused features are the composition and method of use of Gland's proposed generic vasopressin product. Compl. ¶95

U.S. Patent No. 9,981,006 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: May 29, 2018
  • Technology Synopsis: This patent claims a method of increasing blood pressure using a vasopressin formulation defined by its components (acetate buffer), pH (3.6 to 3.9), and a specific ratio of an impurity (SEQ ID NO. 2) to vasopressin. '006 Patent, claim 1 The focus is on the ratio of a specific impurity.
  • Asserted Claims: One or more claims are asserted. Compl. ¶105
  • Accused Features: The accused features are the composition, impurity profile, and method of use of Gland's proposed generic product. Compl. ¶105

U.S. Patent No. 10,010,575 - "Vasopressin Formulations for Use in Treatment of Hypotension"

  • Issued: July 3, 2018
  • Technology Synopsis: This patent claims a method of increasing blood pressure using a vasopressin formulation defined by its components (acetate buffer, dextrose), a specific pH (3.6 to 3.7), and a stability profile (less than 1% degradation after one month at 5°C). '575 Patent, claim 1 This patent claims a highly specific pH range and stability profile under refrigeration.
  • Asserted Claims: One or more claims are asserted. Compl. ¶115
  • Accused Features: The accused features are the composition and method of use of Gland's proposed generic product. Compl. ¶115

III. The Accused Instrumentality

Product Identification

  • Defendant Gland Pharma Limited's proposed generic vasopressin injection products, which are the subject of Abbreviated New Drug Application (ANDA) No. 216963 submitted to the FDA Compl. ¶1 The ANDA seeks approval for 20 units/100ml and 40 units/100ml vasopressin solutions Compl. ¶1

Functionality and Market Context

  • The complaint alleges that Gland's ANDA Products are generic versions of Endo's VASOSTRICT® drug product Compl. ¶1
  • As an ANDA product, Gland's proposed drug is required to have the same active ingredient, route of administration, dosage form, and strength as the reference listed drug, VASOSTRICT® Compl. ¶35 The infringement allegation is a technical one arising under 35 U.S.C. § 271(e)(2)(A), where the submission of an ANDA for a generic drug is considered an act of infringement if the commercial manufacture, use, or sale of that drug would infringe a valid patent.
  • No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or detailed, element-by-element infringement analysis. As this is a Hatch-Waxman case, the infringement allegation is based on the technical specifications of the proposed generic drug as described in the confidential ANDA submission, not on an analysis of a marketed product. The complaint makes general allegations that the product described in Gland's ANDA No. 216963 will, upon approval and commercialization, infringe one or more claims of each of the patents-in-suit (Compl. ¶43; Compl. ¶44; Compl. ¶45). Without access to the confidential ANDA, a detailed infringement analysis is not possible.

  • Identified Points of Contention:
    • Factual Questions: The central issue will be a factual comparison between the formulation, manufacturing processes, and stability data disclosed in Gland's confidential ANDA and the specific quantitative limitations of the asserted claims. The case will require discovery of the ANDA's contents.
    • Scope Questions: A likely point of contention will be whether the specific parameters of Gland's proposed product (e.g., its precise pH, buffer concentration, impurity levels, and degradation profile) fall within the ranges claimed in the various patents-in-suit. For instance, for the '233 patent, a question is whether Gland's product will have a pH within the "3.6 to 3.9" range and exhibit "no more than about 4.0% vasopressin degradation" under the specified conditions '233 Patent, claim 1

V. Key Claim Terms for Construction

  • The Term: "a pH of 3.6 to 3.9" (from '233 Patent, claim 1) and similar pH ranges in other patents.

    • Context and Importance: The patents' specifications identify a narrow pH window as critical for achieving enhanced stability and minimizing impurities. The precise boundaries of this claimed pH range will be central to determining infringement, as even a small deviation in the accused product's pH could potentially avoid literal infringement.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification frequently uses the term "about" when discussing pH values in the examples and description (e.g., '233 Patent, col. 2:37, "a pH of from about 3.0 to about 4.5"), which may support an argument that the claimed numerical endpoints are not absolute and encompass minor variations.
      • Evidence for a Narrower Interpretation: The claims themselves recite a precise range without the word "about." Furthermore, the specification provides data suggesting optimal stability within this very narrow range (e.g., '233 Patent, FIG. 9; '233 Patent, col. 104:25-29), which could be used to argue that the inventors intentionally selected and claimed a specific, critical range, distinguishing it from prior art and other formulations.

  • The Term: "exhibits no more than about [X]% ... degradation" (e.g., "4.0%" in '233 Patent, claim 1).

    • Context and Importance: This functional limitation defines the required stability of the formulation. Infringement will depend on whether Gland's ANDA provides data showing its product meets this stability requirement. The definition of "degradation" and the specific conditions and methods for its measurement will be key.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The use of "about" before the percentage may suggest the number is not a rigid ceiling. A party might argue that standard industry variance in stability testing methods should be considered.
      • Evidence for a Narrower Interpretation: The patents provide detailed examples of how degradation was measured using High-Performance Liquid Chromatography (HPLC) '233 Patent, Example 1, col. 61:25-63:23 A party could argue that "degradation" should be defined and measured strictly according to the methods disclosed in the patent's own examples, limiting the scope to results from that specific analytical technique.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Gland will induce infringement by encouraging and instructing healthcare providers to use the ANDA products in a manner that infringes the asserted method claims. It also alleges contributory infringement on the grounds that Gland's products are especially adapted for an infringing use and have no substantial non-infringing use Compl. ¶¶46-47 Compl. ¶¶56-57
  • Willful Infringement: The complaint alleges that Gland's infringement will be willful, wanton, and deliberate Compl. ¶50 Compl. ¶60 This allegation is based on Gland's pre-suit knowledge of the patents-in-suit, evidenced by its submission of the Paragraph IV Notice Letter to Endo Compl. ¶36

VII. Analyst's Conclusion: Key Questions for the Case

  1. A Factual Question of Formulation: The central dispute will be a direct factual comparison of Gland's confidential ANDA with the patents' claims. The case will turn on whether the specific formulation characteristics described in the ANDA-such as pH, excipients, impurity profiles, and stability data-fall within the precise quantitative limitations recited across the eight asserted patents.

  2. A Definitional Question of Claim Scope: The litigation will likely involve significant disputes over the meaning of key quantitative terms. A core issue will be how narrowly the court construes the claimed numerical ranges for pH (e.g., "3.6 to 3.9") and degradation (e.g., "no more than about 4.0%"). The interpretation of "about" and the relevance of the specific testing methodologies described in the patents will be critical in determining the boundaries of the claims and, consequently, whether Gland's product infringes.

Loading Complaint